SCHEMBL6136316

SCHEMBL6136316

CCCC(=O)N[C@H](C(=O)O)[C@@H](C)CC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.51
FPR2 P25090 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ATM Q13315 1/20 0.45
MAPK1 P28482 2/20 0.44
CA2 P00918 2/20 0.43
CA1 P00915 1/20 0.43
ENPEP Q07075 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MME P08473 1/20 0.41
ACE P12821 1/20 0.41
CPA1 P15085 1/20 0.41
ACE2 Q9BYF1 1/20 0.41
FAAH O00519 1/20 0.40
PLA2G2A P14555 1/20 0.40
PLA2G5 P39877 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136317 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL15692402 0.93 ALDH1A1 (0.53) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL15692339 0.90 ALDH1A1 (0.50) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL9828854 0.89 ALDH1A1 (0.56) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL9828849 0.89 ALDH1A1 (0.56) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL6136152 0.87 FAAH (0.58) ALDH1A1L3MBTL1MEN1KMT2AMAPK1
SCHEMBL4743518 0.87 FAAH (0.58) ALDH1A1L3MBTL1MEN1KMT2AMAPK1
SCHEMBL29048118 0.87 ALDH1A1 (0.58) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL29048120 0.87 ALDH1A1 (0.58) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL15692327 0.87 ALDH1A1 (0.46) ALDH1A1L3MBTL1ENPEPSMN1; SMN2PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946499-B1 N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS ELAN PHARM INC (US) 2005-06-01 EP claimed
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2025-01-02 US disclosed
EP-4299057-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-01-03 EP disclosed
WO-2023084118-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2023-05-19 WO disclosed
EP-4180060-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2023-05-17 EP disclosed
CN-113262719-A Application of peptide-like compound, micro-nano metal powder and preparation method thereof 苏州星翰新材料科技有限公司 2021-08-17 CN disclosed
EP-0946499-B1 N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS ELAN PHARM INC (US) 2005-06-01 EP disclosed
US-4391986-A Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediates therefor and process for producing them NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1983-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID NPPA, BCAT1, ANPEP ALDH1A1 4701/4885L3MBTL1 2521/4885FPR2 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.